Approved HIV Drugs
Approved HIV Drugs
AIDS 2014: Maraviroc Fails To Match Truvada for First-Line HIV Treatment
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 22 July 2014 00:00
- Written by Liz Highleyman
A NRTI-sparing dual antiretroviral regimen containing maraviroc (Selzentry) plus ritonavir-boosted darunavir (Prezista) was found to be less effective than a standard combination with tenofovir/emtricitabine (the drugs in Truvada), according to findings from the MODERN study presented this week at the 20th International AIDS Conference in Melbourne.
People on First HIV Protease Inhibitor May Not Need to Switch After Single Treatment Failure
- Details
- Category: Approved HIV Drugs
- Published on Thursday, 10 July 2014 00:00
- Written by Liz Highleyman
People with HIV who experience a single episode of virological failure while on their first protease inhibitor can safely stay on the same regimen without risk of disease progression, according to a study described in the May 19, advance edition of Clinical Infectious Diseases.
Clinical Trial of Once-Daily Raltegravir Now Underway
- Details
- Category: Approved HIV Drugs
- Published on Wednesday, 11 June 2014 00:00
- Written by Merck
Merck announced this week that treatment-naive participants are now being enrolled in the Phase 3 ONCEMRK trial, which is evaluating the efficacy and safety of a ne formulation of the HIV integrase inhibitor raltegravir (Isentress) taken once rather than twice daily.
Efavirenz Linked to Higher Suicide Risk, May Be Falling Out of Favor
- Details
- Category: Approved HIV Drugs
- Published on Thursday, 03 July 2014 00:00
- Written by Liz Highleyman
The widely used NNRTI efavirenz was associated with a 2-fold increase in the likelihood of suicidal thoughts, attempted suicides, and suicide deaths, though the absolute risk remained small, according to a study described in the July 1 Annals of Internal Medicine. A related review article questioned whether efavirenz should still be considered a preferred option for initial HIV treatment, given its side effects and the development of equally effective and better-tolerated alternatives.
BMS Licenses Atazanavir to Medicines Patent Pool, Allowing Cheaper Generics
- Details
- Category: Approved HIV Drugs
- Published on Wednesday, 18 December 2013 00:00
- Written by Medicines Patent Pool
Bristol-Myers Squibb and the Medicines Patent Pool have reached a licensing agreement that will enable generic drug manufacturers to produce inexpensive versions of the HIV protease inhibitor atazanavir (Reyataz), as well as fixed-dose combinations containing the drug, for use in low-income countries, MPP recently announced. It is the first MPP agreement to cover a preferred second-line therapy.
More Articles...
- HIV Integrase Inhibitor Elvitegravir Approved in European Union
- U.S. HIV Treatment Guidelines Expand Integrase Inhibitor Recommendations
- EACS 2013: Once-daily Raltegravir Effective as Maintenance Therapy; New Formulation in Development
- EACS 2013: Dolutegravir Matches or Beats Other Antiretrovirals for First-line HIV Treatment
Web Design and Development by